We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA Approves New Agent for Multiple Myeloma.
- Authors
Fenichel, Marilyn P.
- Abstract
The article reports on the approval by the U.S. Food and Drug Administration (FDA) on histone deacetylase (HDAC) inhibitor, panobinostat drug, for treatment of multiple myeloma. Topics discussed include the effectiveness of the drug, the side effects of the drug such as fatique, diarrhea, and anemia, and the insights of Frederic Reu, associate staff physician at Cleveland Clinic in Ohio on the drug effectiveness.
- Subjects
DRUG approval; HISTONE deacetylase inhibitors; UNITED States. Food &; Drug Administration; MULTIPLE myeloma treatment; DRUG efficacy; DRUG side effects
- Publication
JNCI: Journal of the National Cancer Institute, 2015, Vol 107, Issue 6, p5
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djv165